Search
Rezafungin
go.drugbank.com/drugs/DB16310ApprovedInvestigational[A258403] In March 2023, the FDA approved rezafungin for injection for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options.
Repotrectinib
go.drugbank.com/drugs/DB16826ApprovedInvestigational[A262066] On November 15th, 2023, the FDA approved repotrectinib under the brand name Augtyro for the treatment of locally advanced or metastatic ROS1-Positive NSCLC.
Crinecerfont
go.drugbank.com/drugs/DB18518ApprovedInvestigational[A264818] Crinecerfont was approved by the FDA in December 2024 as an adjunct to glucocorticoid replacement in patients with CAH.[L51973,L51993] … [A264818] Crinecerfont is a selective antagonist of corticotropin-releasing factor (CRF) type 1 receptor that works to reduce excessive ACTH secretion from the pituitary.
Categories: Corticotropin-releasing Factor Type 1 Receptor AntagonistDaraxonrasib
go.drugbank.com/drugs/DB22308ApprovedInvestigational[L64039,L64040] The FDA approved daraxonrasib on August 26, 2026 for the treatment of adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are
Gadoquatrane
go.drugbank.com/drugs/DB33282Approved[L63930] Bayer announced FDA approval of gadoquatrane on June 15, 2026, for use with MRI in adult and pediatric patients, including term neonates, to detect and visualize lesions with abnormal vascularity
Otilimab
go.drugbank.com/drugs/DB06303InvestigationalInvestigated for the treatment of osteoarthritis and rheumatoid arthritis (RA).
Sufentanil
go.drugbank.com/drugs/DB00708ApprovedInvestigationalSufentanil is an opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent. It is administered by the intravenous, epidural and sublingual routes. Also known as Dsuvia, the subli...
Milrinone
go.drugbank.com/drugs/DB00235ApprovedInvestigational[A228333] It was approved by the FDA on December 31, 1987, and was marketed under the trademark PRIMACOR® by Sanofi-Aventis US before being discontinued.[L31483]
Gemcitabine
go.drugbank.com/drugs/DB00441ApprovedInvestigationalIt is approved by the FDA to treat advanced ovarian cancer in combination with [carboplatin], metastatic breast cancer in combination with [paclitaxel], non-small cell lung cancer in combination with [
Pyridostigmine
go.drugbank.com/drugs/DB00545ApprovedInvestigational[A231009, A231014, L32413, L32418] Pyridostigmine was granted initial FDA approval on April 6, 1955, as an oral tablet. … Myasthenia gravis is an autoimmune disease involving dysfunction at the neuromuscular junction, most commonly due to autoantibodies directed against the acetylcholine receptor (AChR), which results in